RxDoctor Payments Data

Pamela Hopkins

Gerontology · Clio, MINPI 1558739375

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 28.6% of the total.

$1,727in general payments, 2019–2025

Across 102 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$493
  • Otsuka America Pharmaceutical, Inc.$139
  • Amgen$106
  • Pfizer$85
  • Neurocrine Biosciences, Inc.$79
  • Exact Sciences$73
  • plus $752 from 20 others

What the payments were for

  • Food & beverage$1,727100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,727 in reported general payments places this provider in the 75th percentile of 279 gerontology providers in Michigan.

See all gerontology providers in Michigan

Medicare billing

Part B allowed, 2024
$106
Medicare patients
13
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin57$49,243
MounjaroTirzepatide26$27,076
TrulicityDulaglutide25$25,646
EliquisApixaban22$19,746
OzempicSemaglutide19$19,039
Hydroxychloroquine Sulfate56$2,008
Leflunomide37$1,751
MethotrexateMethotrexate Sodium86$1,605
Sulfasalazine125$1,354
Duloxetine Hcl44$1,328
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,147
Atorvastatin Calcium123$1,019
Levothyroxine Sodium98$986
Amitriptyline Hcl26$780
Metoprolol Succinate66$773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$85$19,74622 claims
Novo NordiskOzempic$72$19,03919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 279 gerontology providers in Michigan.

Other gerontology in Clio

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →